It is essential to distinguish medically indicated B12 replacement therapy from commercially marketed wellness injections, as they serve fundamentally different purposes and are subject to different regulatory oversight
Retatrutide, the triple agonist targeting GLP-1, GIP, and glucagon receptors, shows approximately 24% weight loss in phase 2 trials
Meaningful fat loss indicators include measurable changes in body composition, increased energy during fasted states, and visible changes in stubborn fat areas
Semaglutide 2.4 mg for managing overweight and obesity (TA875)
Current Good Manufacturing Practice (CGMP) Regulations
Whether you are brand new to B12 therapy, want guidance before starting self-administration at home, or simply prefer to leave every shot to a provider, we make the process simple